|
|
Analysis of hotspots and frontiers of traditional Chinese medicine treatment of liver cirrhosis based on CiteSpace#br#
#br# |
ZHANG Yingxue SUN Fengxia LI Xiaoling GUO Yufei |
Department of Infections, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China |
|
|
Abstract Objective To make a visual analysis of the literatures related to the treatment of liver cirrhosis with traditional Chinese medicine by CiteSpace software, and to explore the research status and hotspots in this field. Methods The literatures related to the traditional Chinese medicine treatment of liver cirrhosis collected in CKNI from January 2011 to December 2020 were searched, and the cooperation network of authors and institutions, keywords co-occurrence, clustering, and emergent words were analyzed by CiteSpace 5.6.R5. Results A total of 2550 literatures were included. Generally speaking, the annual number of articles published developed steadily. The author cooperation network represented by Wang Tianfang, Xue Xiaolin,Wu Xiuyan, Li Xin, Li Yonggang was large, etc. and the main research institutions were concentrated in traditional Chinese medicine universities and affiliated hospitals, forming multi-cooperation centers. The high-frequency key words included liver cirrhosis, ascites of liver cirrhosis, traditional Chinese medicine, liver cirrhosis in hepatitis B, integration of traditional and western medicine treatment, etc. The research hotspots on the treatment of liver cirrhosis by traditional Chinese medicine gradually transitions to data mining, meta-analysis, traditional Chinese medicine nursing, acupoint application, traditional Chinese medicine umbilical application, traditional Chinese medicine constitution, intestinal flora, etc. Conclusion More attention has been paid to the treatment of liver cirrhosis with traditional Chinese medicine, and the cooperation between different teams needs to be strengthened. The research methods of traditional Chinese medicine in the treatment of liver cirrhosis are more diversified and the treatment methods are more and more comprehensive.
|
|
|
|
|
[1] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
[2] Martini A,Ceranto E,Gatta A,et al. Occult liver disease burden:Analysis from a large general practitioners’database [J]. United European Gastroenterol J,2017,5(7):982-986.
[3] Asrani SK,Devarbhavi H,Eaton J,et al. Burden of liver diseases in the world [J]. J Hepatol,2019,70(1):151-171.
[4] Lee NY,Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment [J]. Int J Mol Sci,2020,22(1):199.
[5] 贾继东.重视肝硬化患者长期管理[J].临床肝胆病杂志,2021,37(1):12-13.
[6] 陈阳,李莹,张玮,等.中医药抗肝硬化作用机制的研究进展[J].医学综述,2020,26(8):1593-1597.
[7] Liu S,Sun YP,Gao XL,et al. Knowledge domain and emerging trends in Alzheimer’s disease:a scientometric review based on CiteSpace analysis [J]. Neural Regen Res,2019,14(9):1643-1650.
[8] 张维益,曹柳娇,李艳飞,等.衰弱研究的热点与前沿分析:基于CiteSpace的可视化分析[J].中国循证医学杂志,2020,20(11):1308-1315.
[9] 陈悦,陈超美,刘则渊,等.CiteSpace知识图谱的方法论功能[J].科学学研究,2015,33(2):242-253.
[10] Zhou WC,Zhang QB,Qiao L. Pathogenesis of liver cirrhosis [J]. World J Gastroenterol,2014,20(23):7312-7324.
[11] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:the major impact of China [J]. Hepatology,2014,60(6):2099-2108.
[12] 郭洁婉,蒋开平,胡洪涛,等.补肾填精法治疗乙型肝炎肝硬化(代偿期)探讨[J].辽宁中医药大学学报,2019, 21(12):190-193.
[13] 李聪聪,石雪娅,段荣章.肝硬化腹水的中医药诊疗进展[J].中医临床研究,2018,10(9):45-47.
[14] 赵强,邢枫,刘成海.肝硬化腹水的中医药治疗研究进展[J].中华中医药杂志,2018,33(10):4557-4559.
[15] 王艳萍,李文静,洪博.基于网络药理学探讨十枣汤治疗肝硬化腹水的作用机制[J].中国医药导报,2021,18(19):32-35,198.
[16] 阮博文,周晓玲,覃凤传,等.柴胡当归散治疗少阳太阴合病证乙肝肝硬化腹水[J].中国临床研究,2021,34(1):102-106.
[17] 梅泰中,许吉,张洋,等.2012~2017年中医药数据挖掘研究状况分析[J].数理医药学杂志,2020,33(1):70-72.
[18] 叶思思.数据挖掘肝硬化古今名老中医内治规律[D].广州:广州中医药大学,2020.
[19] 余学竟,赖国权,韦翠,等.中医外治法对肝硬化腹水的Meta分析[J].辽宁中医杂志,2020,47(11):17-26.
[20] 穆东升.中医对肝硬化记载及辨证论治概况[J].辽宁中医药大学学报,2020,22(6):129-132.
[21] 周倩倩,邢枫,张雅丽,等.中医护理肝硬化腹水研究进展[J].河南中医,2021,41(4):641-644.
[22] 林辉瑶,康燕能,洪燕秋,等.乙肝肝硬化中医体质研究现状[J].中医临床研究,2019,11(1):143-145.
[23] 纪留娟,钱志平,王介非.代谢组学在HBV相关肝脏疾病中的研究进展[J].肝脏,2016,21(9):774-777.
[24] Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine [J]. Nat Rev Drug Discov,2016,15(7):473-484.
[25] 孙桂江,姜埃利,李遇伯,等.代谢组学在疾病诊断及中药治疗的研究进展[J].中国中西医结合杂志,2021,41(1):122-125.
[26] Philips CA,Augustine P,Yerol PK,et al. Modulating the Intestinal Microbiota:Therapeutic Opportunities in Liver Disease [J]. J Clin Transl Hepatol,2020,8(1):87-99.
[27] Solé C,Guilly S,Da Silva K,et al.基于定量宏基因组学评估肝硬化患者肠道菌群的变化与慢加急性肝衰竭及预后的关系[J].临床肝胆病杂志,2020,36(11):2536.
[28] 陈慧婷,周永健.肠道微生态影响肝脏疾病的若干进展与思考[J].实用肝脏病杂志,2020,23(6):765-768. |
|
|
|